TrialResults-center.org

Menu

Description Results NMA

Group by...

in first

in second

in third

pdf

pathology

Demonstrated benefit and harm

k

acute coronary syndrome

versus heparin

No demonstrated result for efficacy

Trial	control	p<0.05	harm	NS
Klootwijk, 1999	Efegatran vs heparin

Trial

Treatments

Patients

Method

Klootwijk, 1999

Efegatran 0.1–0.3 mg/kg bolus; 0.105–1.200 mg /kg/h infusion for 48h (n=432)

vs.

UFH 5000 IU bolus; 1000 IU/h infusion (n=0)

patients with unstable angina

open

Parallel groups

Sample size: 432/0

Primary endpoint: none defined

FU duration: 30 days

Modal title

- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy -